Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry
Journal of Pediatric Gastroenterology and Nutrition · 2026-11 · 83 (5) · 810-818
DOI: 10.1002/jpn3.70544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 23.08.2026. Verfasst von Anna Schmidt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Child Development. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda; Abbvie; Dr. Falk Pharma; Sanofi; Mirum.
Abstract (Originalsprache)
Objective
Different therapies may affect the growth and development of children and adolescents with inflammatory bowel disease (IBD) supporting specific therapy algorithms for paediatric Crohn's disease (CD) and ulcerative colitis (UC).
Methods
Growth and development data from the German–Austrian CEDATA‐GPGE registry entered between 2004 and 2021 were analysed for 0–18 year olds with complete follow‐up on diagnoses and therapies. Standard deviation scores (SDS) for height, weight, and body mass index (BMI) were compared between initial diagnosis (t0) and 4‐year follow‐up (t4) within groups using multivariate analysis. Factors included gender, age, disease type, age at diagnosis, and initial therapies.
Results
Data from 450 patients (CD: 303; UC: 147) were analysed. At t0, SDS values for height (mean value [ M ] = −0.37, standard deviation [SD] = 1.07), weight ( M = −0.57, SD = 0.92), and BMI ( M = −0.55, SD = 0.95) were below average. The SDS values for weight and BMI increased significantly between t0 and t4 with small effect sizes, whereas the SDS value for height did not. Diagnosis, gender, disease localisation, and remission after 6 months did not influence height SDS. Patients treated exclusively with enteral nutrition (EEN) or azathioprine showed improved weight and BMI development, whereas corticosteroids led to weight gain.
Conclusion
The analysis showed that EEN and disease control significantly improve weight and BMI in children with IBD, SDS‐H catch‐up was only observed in the subgroup with growth impairment at initial diagnosis. Children with severe or recurrent flares, or persistent nutritional deficits, are at increased risk of growth impairment and require close medical monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
- General Paediatrics and Neonatology, University Children's Hospital, Justus Liebig University Giessen, Giessen, Germany.
ORCID-Profile: Anna Schmidt, Ilse Broekaert
Förderung
- Takeda; Abbvie; Dr. Falk Pharma; Sanofi; Mirum
Zitieren
APA
Schmidt, A., Broekaert, I., Hünseler, C., de Laffolie, J., & CEDATA Study Group (2026). Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry. Journal of Pediatric Gastroenterology and Nutrition, 83(5), 810-818. https://doi.org/10.1002/jpn3.70544
Vancouver
Schmidt A, Broekaert I, Hünseler C, de Laffolie J, CEDATA Study Group. Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry. Journal of Pediatric Gastroenterology and Nutrition. 2026;83(5):810-818. doi:10.1002/jpn3.70544
BibTeX
@article{Schmidt2026,
author = {Schmidt, Anna and Broekaert, Ilse and Hünseler, Christoph and de Laffolie, Jan and CEDATA Study Group, CEDATA Study Group},
title = {Growth and development in paediatric onset inflammatory bowel disease: Data analysis from the CEDATA registry},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2026},
volume = {83},
number = {5},
pages = {810--818},
doi = {10.1002/jpn3.70544}
}
EUVIMED